20.7.2017 14:02 | Business Wire
Philogen Enters into Multi-Target Research Agreement with Boehringer Ingelheim in the Field Of DNA-Encoded Chemistry
Philogen S.p.A., a privately owned biotechnology company today announced a collaboration and license agreement with Boehringer Ingelheim to discover and optimize novel small molecule-based therapeutics using Philochem’s proprietary Encoded Self-Assembling Chemical (ESAC) Library Technology platform.
“We are extremely pleased to announce a new collaboration with Boehringer Ingelheim, a very innovative pharmaceutical company with a long tradition both in the field of therapeutic proteins and of small-molecule pharmaceuticals. After the initial clinical collaboration with Boehringer Ingelheim in the immune-oncology space announced in 2016, this second partnership underlines the good relationship between the two companies. We are both committed to the creation of new pharmaceutical agents, which may help treat serious unmet medical needs and provide a benefit to patients. ESAC technology is ideally suited for the identification of synergistic chemical fragments, which recognize adjacent binding sites on the surface of the target protein of interest. We are confident that ESAC technology will facilitate hit and lead discovery activities, complementing the strong Medicinal Chemistry technologies already established at Boehringer Ingelheim”, commented Prof. Dario Neri, co-founder and President of the Scientific Advisory Board of Philogen.
ESAC technology represents an innovative proprietary methodology for the construction and screening of DNA-encoded chemical libraries of unprecedented size and quality. ESAC libraries, which are generated by the combinatorial self-assembly of encoded libraries of very high purity, are different compared to conventional single-pharmacophore chemical libraries.
Darryl McConnell, Vice President and Head, Boehringer Ingelheim Research Site Austria, said, “We are very excited about the opportunity to apply Philochem’s DNA-encoded library technology to drugging intractable proteins. We believe that Philochem’s unique chemistry combined with Boehringer Ingelheim’s capabilities in discovering novel drugs could accelerate the optimization of chemical starting points to potent drug candidates”.
No financial details of the agreement were released.
About the Philogen group
Philogen is a Swiss-Italian clinical-stage company engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information please visit www.philogen.com .
About Philochem’s ESAC platform and DNA-Encoded Chemistry technology
The proprietary ESAC platform and DNA-Encoded Chemistry technology were developed by Philochem scientists in collaboration with the group of Prof. Dario Neri at ETH Zurich during the past decade. These two powerful and complementary discovery technologies allow to screen up to billions small molecules and to further optimize the hit compounds in a fully automatic, DNA-tagged, fragment-based drug discovery manner.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
NC-LENOVO-NCTA18.8.2017 02:06 | pressemeddelelse
Lenovo Continues to Gain Momentum in First Quarter FY 2017/18
SPIRENT-COMMUNICATIONS17.8.2017 17:59 | pressemeddelelse
Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye
BIZWIRETV17.8.2017 14:10 | pressemeddelelse
Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate
PA-PSIOXUS-THERAPEUTICS17.8.2017 09:02 | pressemeddelelse
PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence
SMARSH-INC/COGNIA17.8.2017 09:01 | pressemeddelelse
Smarsh Adds Voice Archiving Offering with Acquisition of London-Based Cognia
TX-SCHLUMBERGER-LIMITED16.8.2017 23:25 | pressemeddelelse
Schlumberger Announces Third-Quarter 2017 Results Conference Call
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum